

Haematologica
HAEMATOL/2019/217950
Version 3

Molecular quantification of tissue disease burden is a new biomarker
and independent predictor of survival in mastocytosis

Georg Greiner, Michael Gurbisz, Franz Ratzinger, Nadine Witzeneder,
Svenja Verena Class, Gregor Eisenwort, Ingrid Simonitsch-Klupp,
Harald Esterbauer, Matthias Mayerhofer, Leonhard Müllauer, Wolfgang
R. Sperr, Peter Valent, and Gregor Hoermann

Disclosures: P.V. served as a consultant in a global Novartis trial investigating the effects of midostaurin in patients with advanced systemic mastocytosis and received honoraria and research grants from Novartis, Blueprint, and Deciphera. W.R.S. received honoraria from Novartis. G.H. received honoraria and research grants from Novartis. The authors declare no other competing financial interests.

Contributions: G.G., M.G., N.W., and S.-V.C. performed molecular tests and analyzed the data. G.G., G.E., I.S.-K., H.E., M.M., L.M., W.R.S., P.V., and G.H. obtained and analyzed clinical data. G.G., and F.R. performed statistical analyses. G.G., P.V., and G.H. designed the study and wrote the paper. All authors revised and approved the manuscript.